Showing results (121-130 of 164) with videos related to
Sort By:
Pageof 17
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|February 14, 2024
Kinome-Wide Synthetic Lethal Screen Identifies PANK4 as a Modulator of Temozolomide Resistance in GlioblastomaViviana Vella, Angeliki Ditsiou, Anna Chalari, et al.Cell Discovery|February 5, 2026
Integrating single-nucleus barcoding with spatial transcriptomics via Stamp-seq to reveal immunotherapy response-enhancing functional modules in NSCLCYitong Pan, Huan Yan, Jinhuan Han, et al.Iscience|October 1, 2024
Development of a prognostic nomogram for advanced non-small cell lung cancer using clinical characteristicsHaoyue Qin, Zhe Huang, Huan Yan, et al.Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|January 29, 2021
The Beneficial Role of Sunitinib in Tumor Immune Surveillance by Regulating Tumor PD-L1Hui Li, Xinwei Kuang, Long Liang, et al.Frontiers in Immunology|November 17, 2022
The duration and breadth of antibody responses to 3-dose of inactivated COVID-19 vaccinations in healthy blood donors: An observational studyShanhai Ou, Zehong Huang, Miaoling Lan, et al.JAMA Network Open|March 20, 2020
Efficacy and Safety of Apatinib Plus Vinorelbine in Patients With Wild-Type Advanced Non-Small Cell Lung Cancer After Second-Line Treatment Failure: A Nonrandomized Clinical TrialXiangyu Zhang, Yi Xiong, Qing Xia, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 3, 2025
Taletrectinib in ROS1+ Non-Small Cell Lung Cancer: TRUSTMaurice Pérol, Wei Li, Nathan A Pennell, et al.Lung Cancer (Amsterdam, Netherlands)|November 30, 2024
The efficacy of continuing osimertinib with platinum pemetrexed chemotherapy upon progression in patients with metastatic non-small cell lung cancer harboring sensitizing EGFR mutationsTejas Patil, Dexiang Gao, Alexander Watson, et al.Lung Cancer (Amsterdam, Netherlands)|September 2, 2023
Dynamic cytokines signature predicts survival outcome from severe Immune-related hepatitis with PD-1/PD-L1 blockade in lung cancerLiang Zeng, Yuling Zhou, Qinqin Xu, et al.Med (New York, N.Y.)|March 23, 2024
First-in-human phase I study of BEBT-109 in previously treated EGFR exon 20 insertion-mutated advanced non-small cell lung cancerLiang Zeng, Lianxi Song, Li Liu, et al.Pageof 17